Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
April 14, 2022 07:30 ET
|
Agile Therapeutics, Inc.
29% increase in Twirla cycles27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare...
Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
April 11, 2022 07:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale...
Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)
April 07, 2022 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that data from the company’s first-year of postmarketing...
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
March 31, 2022 07:30 ET
|
Agile Therapeutics, Inc.
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system, while highlighting the power of...
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
March 30, 2022 16:05 ET
|
Agile Therapeutics, Inc.
Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected...
Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering
March 14, 2022 18:07 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed...
Agile Therapeutics Announces $4.85 Million Registered Direct Offering
March 14, 2022 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has entered...
Agile Therapeutics to Participate in Upcoming March Investor Events
March 11, 2022 08:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will...
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022
March 07, 2022 08:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2021 financial...
Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
January 12, 2022 17:29 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports...